News und Analysen
Elanco Animal Health Q2 Earnings Call Highlights
Key Points
- Interested in Elanco Animal Health Incorporated? Here are five stocks we like better.
- Strong Q2 performance: Elanco reported revenue of $1.368 billion, up 10% year over year, while
Becton, Dickinson and Company Q3 Earnings Call Highlights
Key Points
- Interested in Becton, Dickinson and Company? Here are five stocks we like better.
- Strong Q3 performance: Becton, Dickinson and Company reported $5 billion in fiscal 2026
Zai Lab Q2 Earnings Call Highlights
Key Points
- Interested in Zai Lab Limited Unsponsored ADR? Here are five stocks we like better.
- Q2 net product revenue rose 11% sequentially to $105.8 million, supported by VYVGART volume
REGENXBIO Q2 Earnings Call Highlights
Key Points
- Interested in REGENXBIO Inc.? Here are five stocks we like better.
- RGX-202 Duchenne program advanced toward filing: REGENXBIO completed enrollment and dosing in its confirmatory
QuidelOrtho Q2 Earnings Call Highlights
Key Points
- Interested in QuidelOrtho Corporation? Here are five stocks we like better.
- Second-quarter revenue rose 2% to $631 million on a constant-currency basis, while revenue outside China
OmniAb Q2 Earnings Call Highlights
OmniAb (NASDAQ:OABI) reported higher second-quarter revenue and a narrower net loss as milestone payments from partner programs increased, while the company raised its full-year 2026 revenue and
Bayer Aktie: Glyphosat-Anhörung frühestens am 14. September
Bayer und die Klägerseite im US-Glyphosat-Streit haben gemeinsam beantragt, die Anhörung zur endgültigen Genehmigung…
Der Beitrag Bayer Aktie: Glyphosat-Anhörung frühestens am 14. September erschien
CVRx Q2 Earnings Call Highlights
Key Points
- Interested in CVRx, Inc.? Here are five stocks we like better.
- CVRx lowered its 2026 outlook due to sales-force turnover, slower territory-manager productivity ramps and
Arcturus Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Arcturus Therapeutics Holdings Inc.? Here are five stocks we like better.
- ARCT-032 cystic fibrosis study remains on track: Phase II enrollment is active in the U.S
Ironwood Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ironwood Pharmaceuticals, Inc.? Here are five stocks we like better.
- LINZESS sales strengthened: U.S. second-quarter sales rose 14% to $282.3 million, prompting
Genmab A/S Q2 Earnings Call Highlights
Key Points
- Interested in Genmab A/S Sponsored ADR? Here are five stocks we like better.
- Genmab raised its 2026 outlook, now forecasting revenue of DKK 4.3 billion–DKK 4.5 billion and operating
Merck KGaA Q2 Earnings Call Highlights
Key Points
- Interested in Merck KGaA? Here are five stocks we like better.
- Merck KGaA reported strong Q2 growth, with organic sales up 4.1% and EBITDA pre rising 9.3% organically to €1.6
Bayer Aktie: UBS hebt Kursziel auf 62 Euro
Bayer sorgt an diesem Donnerstag gleich mit zwei Nachrichten für Bewegung: Der Konzern hat…
Der Beitrag Bayer Aktie: UBS hebt Kursziel auf 62 Euro erschien zuerst auf kapitalmarktexperten.de.
Quelle
CVS Health Q2 Earnings Call Highlights
Key Points
- Interested in CVS Health Corporation? Here are five stocks we like better.
- CVS Health exceeded second-quarter expectations, reporting $106 billion in revenue, adjusted EPS of $2.58
EQS-News: Fresenius stellt auf Namensaktien um – automatische Umwandlung für Aktionärinnen und Aktionäre
EQS-News: Fresenius stellt auf Namensaktien um – automatische Umwandlung für Aktionärinnen und Aktionäre
Novartis Aktie: Zacks senkt Q3-EPS auf 2,22 Dollar
Die Aktie des Schweizer Pharmakonzerns Novartis rückt zum Ende der Handelswoche verstärkt in das…
Der Beitrag Novartis Aktie: Zacks senkt Q3-EPS auf 2,22 Dollar erschien zuerst auf kapitalmarktexper
Sarepta Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Sarepta Therapeutics, Inc.? Here are five stocks we like better.
- Q2 revenue fell 34% to $401 million, primarily due to lower ELEVIDYS sales, although Sarepta reported
Sight Sciences Q2 Earnings Call Highlights
Key Points
- Interested in Sight Sciences, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 20% year over year to $23.4 million, driven by 8% growth in interventional
EQS-News: Carl Zeiss Meditec mit währungsbereinigt stabiler Umsatzentwicklung nach neun Monaten 2025/26
EQS-News: Carl Zeiss Meditec mit währungsbereinigt stabiler Umsatzentwicklung nach neun Monaten 2025/26
GRAIL Q2 Earnings Call Highlights
Key Points
- Interested in GRAIL, Inc.? Here are five stocks we like better.
- Revenue and Galleri volumes grew strongly: Second-quarter revenue increased 26% year over year to $44.7 million, while
AbCellera Biologics Q2 Earnings Call Highlights
Key Points
- Interested in AbCellera Biologics Inc.? Here are five stocks we like better.
- ABCL635 data is expected very soon: AbCellera completed enrollment and initial dosing ahead of schedule in
Royalty Pharma Q2 Earnings Call Highlights
Key Points
- Interested in Royalty Pharma PLC? Here are five stocks we like better.
- Royalty Pharma raised its 2026 outlook for the second consecutive quarter, now forecasting portfolio receipts
Bayer Aktie: Nettofinanzverschuldung auf 29-30 Milliarden gesenkt
Bayer hat am Dienstag mit den Zahlen für das zweite Quartal 2026 einen Wendepunkt…
Der Beitrag Bayer Aktie: Nettofinanzverschuldung auf 29-30 Milliarden gesenkt erschien zuerst auf kapitalmarktexper
Pfizer Q2 Earnings Call Highlights
Key Points
- Interested in Pfizer Inc.? Here are five stocks we like better.
- Pfizer exceeded expectations in Q2 2026, reporting $15 billion in revenue and adjusted EPS of $0.77. The company
Pharma-Woche der Wahrheit: BioNTech enttäuscht, Novartis punktet bei Pluvicto
Ein Milliardenverlust bei BioNTech, eine erweiterte Zulassung für Novartis‘ Krebstherapie Pluvicto und gleich zwei…
Der Beitrag Pharma-Woche der Wahrheit: BioNTech enttäuscht, Novartis punktet bei